<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>17</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="epublish">
        <Year>2023</Year>
        <Month>10</Month>
        <Day>14</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Combined Haploidentical Hematopoetic Stem Cell Transplantation and Liver Transplantation in a Pediatric Patient</title>
    <FirstPage>291</FirstPage>
    <LastPage>295</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Vedat</FirstName>
        <LastName>Uygun</LastName>
        <affiliation locale="en_US">&#x130;stinye University, Faculty of Medicine, MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Antalya, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>&#x130;brahim</FirstName>
        <LastName>Aliosmano&#x11F;lu</LastName>
        <affiliation locale="en_US">&#x130;stinye University, Faculty of Medicine, MedicalPark Antalya Hospital, Department of General Surgery, Antalya, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>Hayriye</FirstName>
        <LastName>Dalo&#x11F;lu</LastName>
        <affiliation locale="en_US">Antalya Bilim University, Faculty of Health Sciences, MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Antalya, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>Seda</FirstName>
        <LastName>&#xF6;zt&#xFC;rkmen</LastName>
        <affiliation locale="en_US">MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Antalya, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>Koray</FirstName>
        <LastName>yal&#xE7;&#x131;n</LastName>
        <affiliation locale="en_US">Bah&#xE7;e&#x15F;ehir University, Faculty of Medicine, MedicalPark G&#xF6;ztepe Hospital, Department of Pediatric Bone Marrow Transplantation Unit, &#x130;stanbul, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>G&#xFC;ls&#xFC;n</FirstName>
        <LastName>Karasu</LastName>
        <affiliation locale="en_US">MedicalPark G&#xF6;ztepe Hospital, Department of Pediatric Bone Marrow Transplantation Unit, &#x130;stanbul, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>Akif</FirstName>
        <LastName>Ye&#x15F;ilipek</LastName>
        <affiliation locale="en_US">MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Antalya, Turkey</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2022</Year>
        <Month>07</Month>
        <Day>01</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2023</Year>
        <Month>08</Month>
        <Day>21</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Solid organ transplantation from the same donor is an established procedure for end-stage organ failure that developed after a previous hematopoietic stem cell transplantation (HSCT); however, it is rarely done in patients transplanted with unmanipulated haplo-HSCT. There are no pediatric reports regarding the long-term performance of organ transplantation after haplo-HSCT with post-transplant cyclophosphamide (PTCY).
A juvenile myelomonocytic leukemia patient, who underwent unmanipulated haplo-HSCT with PTCY from her mother at the age of 3 years, developed chronic liver graft versus host disease (GvHD) which was refractory to specific GvHD treatment. Liver transplantation (LT) from her mother (the donor of her haplo-HSCT) was decided as the next line of treatment.
LT was performed on day 540 post-HSCT, and the donor's left lateral segment was appropriately removed and attached to the recipient. The symptoms of GvHD completely regressed in a month. The patient died on day 121 after LT, because of a possible hepato-pulmonary syndrome.
Organ failure can develop after allo-HSCT secondary to GvHD and therefore performing HSCT from a haplo-donor may be superior to a matched unrelated donor in terms of subsequent organ transplantation for organ failure.</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1871</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1871/1005</pdf_url>
  </Article>
</Articles>
